Thymalin
Also known as: Thymaline, Thymic factor, Thymus polypeptide extract, Cytomedins (thymalin), Thymic hormone preparation
Polypeptide complex / thymic peptide immunomodulator (derived from bovine/cattle thymus extract)
What it is
Thymalin is a thymic peptide preparation used in Russia for immune modulation, infectious disease, and aging-related immune decline. It works by supporting the immune system's regulatory functions, including T-cell activity. Not FDA-approved; approved and used clinically in Russia; most evidence comes from Russian clinical trials with limited independent replication.
The scientific side
Thymalin is a polypeptide complex isolated from the thymus gland that regulates immune system function. Its active dipeptide components include KE (which stimulates cellular immunity and activates macrophages, lymphocytes, thymocytes, and neutrophils) and EW (which reduces angiotensin-induced vasoconstriction and inhibits ACE2, the target protein of SARS-CoV-2). Thymalin stimulates differentiation of hematopoietic stem cells (HSC), reducing expression of CD44 and CD117 (stem cell markers) by 2–3 times while increasing CD28 expression (marker of mature T lymphocytes) by 6.8 times, thereby promoting maturation of CD117+ cells into CD28+ T lymphocytes. It normalizes LDH isoenzyme spectra and cyclase systems in lymphocytes, and promotes expression of differentiation antigens on T-lymphocyte surfaces, restoring functional T-lymphocyte activity. In the context of COVID-19, Thymalin and its dipeptide components EW and KE reduce synthesis of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α in human peripheral blood mononuclear cells by 1.4–6.0 times, with potential targets including AKT1, AKT2, ACE2, CYSLTR1, and CHUK genes involved in cytokine storm pathogenesis. In bone healing, thymalin injection activates reparative osteogenesis by reducing neutrophil leukocytes, increasing monocytes, macrophages, lymphocytes, and fibroblastic differon cells, and modulating osteoblast and osteoclast activity. Thymalin also modulates hemostasis, normalizing blood coagulation, fibrinolysis, and fibrinogen levels (PMID 6546722, PMID 3488603).
Class: Polypeptide complex / thymic peptide immunomodulator (derived from bovine/cattle thymus extract)
Administration & storage
- Administration
- Intramuscular injection — referenced in ophthalmic herpes study (PMID: 1763455)Subcutaneous injection — referenced in ophthalmic herpes study (PMID: 1763455)Intraosseous (intraosteal) lavage — reported in pediatric odontogenic osteomyelitis (PMID: 2326818)Intralymphatic (endolymphatic) administration — reported in appendicular peritonitis (PMID: 3754913)Soft tissue injection (perilesionalsurrounding bone defect) — reported in mandibular bone defect rat model (PMID: 38431810)
- Storage
- No abstracts in the reviewed literature address storage conditions for Thymalin.
- Cautions
- No formal pharmacokinetic (PK) data in humans were reported in the reviewed abstracts — the absorption, distribution, metabolism, and elimination profile of Thymalin is not established from the reviewed literature.,Thymalin is described as a polypeptide extract from cattle (bovine) thymus; risk of biological contaminants or batch-to-batch variability inherent to animal-derived extracts should be considered.,The majority of human clinical data in the reviewed abstracts are observational or non-randomized comparative studies from the 1980s–1990s, limiting the strength of safety conclusions.,Use with heparin was specifically noted to be indicated for elderly patients and those at higher thromboformation risk — co-administration with anticoagulants warrants caution and clinical supervision.,Sterile technique is essential for all injection routes reported (intramuscular, subcutaneous, intraosseous, intralymphatic, soft tissue).
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- COVID-19 (severe) — immunomodulation and reduction of cytokine storm Mixed
- In a retrospective study of severe COVID-19 patients (middle-aged and elderly), Thymalin added to basic therapy reduced hospital mortality to 20.6% vs. 40.9% with standard therapy and 28.4% with Tocilizumab. Thymalin increased lymphocytes and monocytes by 2-fold, increased leukocytes 1.3-fold and platelets 1.5-fold, wh PMID 36169363 Kuznik et al., Advances in gerontology, 2022
- In an LPS-induced in vitro model of inflammation using human peripheral blood mononuclear cells, Thymalin and its EW and KE dipeptides reduced synthesis of IL-1β, IL-6, and TNF-α by 1.4–6.0 times. Molecular docking identified AKT1, AKT2, ACE2, CYSLTR1, and CHUK as potential gene targets. PMID 37686182 Linkova et al., International Journal of Molecular Sciences, 2023
- Thymalin reduced CD44 and CD117 expression on human HSCs by 2–3 times and increased CD28 expression by 6.8 times in cell culture, suggesting stimulation of differentiation into mature T lymphocytes relevant to antiviral immunity in COVID-19. PMID 33237528 Khavinson et al., Bulletin of Experimental Biology and Medicine, 2020
- Geroprotection / longevity and age-related disease prevention Human observational
- In 266 elderly persons followed for 6–8 years with bioregulator applied for the first 2–3 years, Thymalin treatment was associated with 2.0–2.1-fold decrease in mortality, 2.0–2.4-fold decrease in acute respiratory disease incidence, and improved cardiovascular, endocrine, immune, and nervous system indices. Combined T PMID 14523363 Khavinson & Morozov, Neuro Endocrinology Letters, 2003
- Corroborating 266-patient study: Thymalin-treated group showed 2.0–2.1-fold mortality reduction, reduced incidence of ischemic heart disease, hypertension, osteoarthrosis, and osteoporosis compared to control. PMID 12577695 Khavinson & Morozov, Advances in Gerontology, 2002
- Reparative osteogenesis / bone defect healing Animal studies only
- In 48 WAG rats with mandibular bone defects, combined hydroxyapatite graft plus soft-tissue thymalin injection significantly activated reparative osteogenesis vs. either treatment alone, with improved immune cell dynamics and bone mineralization. PMID 38431810 Boiko et al., Wiadomosci lekarskie, 2024
- Inflammatory and proliferative modulation in monocyte/macrophage cells (in vitro) In vitro only
- The Thymalin peptide complex increased tyrosine phosphorylation of mitogen-activated cytoplasmic kinases in THP-1 cells, inhibited TNF and IL-6 expression stimulated by LPS in differentiated THP-1 macrophages, and reduced adhesion of THP-1 cells to LPS-activated endothelial cells (HUVECs), suggesting anti-inflammatory PMID 35408963 Avolio et al., International Journal of Molecular Sciences, 2022
- Hematopoietic stem cell differentiation (in vitro) In vitro only
- Thymalin reduced CD44 and CD117 expression by 2–3 times and increased CD28 expression by 6.8 times in cultured human hematopoietic stem cells from fetal blood, indicating promotion of T lymphocyte differentiation. PMID 33237528 Khavinson et al., Bulletin of Experimental Biology and Medicine, 2020
- Pulmonary tuberculosis (adjunct to chemotherapy) Human observational
- Differential administration of thymalin combined with chemotherapy in 60 patients with destructive pulmonary tuberculosis shortened hospital stay and increased treatment efficacy with normalizing effects on immune system recovery. PMID 2080155 Kogosova et al., Problemy tuberkuleza, 1990
- In 116 patients with infiltrative destructive pulmonary tuberculosis, the main group (76 persons) receiving thymalin at early stages of chemotherapy showed improved treatment efficacy with faster restoration of cellular immunity indices compared to the control group. PMID 2617987 Ivanova, Vrachebnoe delo, 1989
- Chronic lymphoid leukemia (adjunct therapy) Human observational
- In patients with B-variant chronic lympholeukemia (Stage II), thymalin inclusion in complex treatment improved functional activity of lymphoid cells and reduced time to clinical and hematological remission. PMID 2750120 Babenko et al., Vrachebnoe delo, 1989
- Combined use of thymalin and plasmapheresis in chronic lymphoid leukemia patients resulted in more rapid attainment of clinical and hematological compensation compared with chemotherapy alone, with improved functional activity of the lymphoid system. PMID 9670669 Tretiak et al., Likars'ka sprava, 1998
- Ischemic heart disease / angina pectoris Human observational
- Thymalin in multimodality therapy of CHD patients with angina normalized cellular and humoral immunity, slowed blood coagulation, decreased fibrinogen and FDP concentration, enhanced fibrinolysis, and was associated with more rapid disappearance of pain syndrome. PMID 3488603 Kuznik et al., Terapevticheskii arkhiv, 1986
- In 156 patients with exertion stenocardia (functional class II–IV), complex treatment with thymalin increased thymic factor levels, normalized lipid metabolism, increased myocardial contractile function, and increased treatment efficacy. PMID 1481512 Shustval', Likars'ka sprava, 1992
- Acute peritonitis (adjunct therapy) Human observational
- In 63 patients with acute peritonitis, thymalin alone or combined with heparin facilitated quicker arrest of the pathological process. Combined thymalin and heparin was indicated especially for elderly patients and those at higher thromboformation risk. PMID 3754668 Kokotov et al., Vestnik khirurgii, 1986
- Cervical carcinoma and uterine cancer (adjunct to radiotherapy/hormonotherapy) Human observational
- In 38 patients with advanced cervical carcinoma, radiation supplemented with thymalin immunotherapy allowed wider application of radical surgery and better outcomes versus 58 controls receiving radiotherapy alone. PMID 2014686 Vishnevskaya et al., Voprosy onkologii, 1991
- Thymalin as a component of complex treatment (hormonotherapy + surgery) in 35 of 111 endometrial cancer patients demonstrated positive effects on cell immunity and clinico-morphological parameters. PMID 2245808 Bakhidze & Bokhman, European Journal of Gynaecological Oncology, 1990
- Herpetic stomatitis in children Human observational
- In 44 children with acute and relapsing herpetic stomatitis, thymalin therapy did not cause rapid abatement of acute symptoms but achieved a stable antirelapse effect in children at high risk of recurrence. PMID 8191521 Kazantseva & Bikbulatov, Stomatologiia, 1994
- Multiple sclerosis (homeostatic correction) Human observational
- In patients with multiple sclerosis, arginine-vasopressin combined with thymalin was advised for correction of homeostatic abnormalities and secondary disease prophylaxis based on immune-endocrine-nervous system interaction data. PMID 2160161 Akimov et al., Zhurnal nevropatologii, 1990
- Parkinsonism (adjunct therapy) Human observational
- In 15 patients with stage IB–2A idiopathic parkinsonism (ages 45–72), thymalin treatment was associated with positive course in physical/mental well-being, improvement of the parkinsonian triad (tremor, rigidity, hypokinesia), and significant decrement in alpha-rhythm power in anterocentral brain regions on EEG mapping PMID 10424021 Musienko, Likars'ka sprava, 1999
- Therapy-resistant schizophrenia (adjunct therapy) Human observational
- Thymaline combined with psychotropic drugs in 36 therapeutically resistant schizophrenia patients with immune abnormalities enhanced treatment efficacy, reduced neuroleptic complications, and correlated with normalization of immune abnormalities. PMID 2163147 Govorin & Stupina, Zhurnal nevropatologii, 1990
- Non-specific lung diseases (immunocorrection) Human observational
- In 21 of 35 patients with non-specific pulmonary diseases, thymalin in relatively small doses (5 ml, 4–6 injections per course) normalized lymphocyte count and OKT-4+/OKT-8+ subpopulations; beneficial clinical action was most evident in patients with preserved phagocytic component function. PMID 2741122 Dovnar et al., Terapevticheskii arkhiv, 1989
- Psoriasis (immunomodulation) Human observational
- Thymalin in combined therapy of psoriasis patients resulted in complete or incomplete normalization of immunity and hemostasis parameters with improvement in clinical status. PMID 2609748 Isaeva et al., Vestnik dermatologii, 1989
- Radiation-induced cytogenetic effects (modification) Human observational
- Thymalin was identified as one of several substances that can modify radiation-induced cytogenetic effects in peripheral blood lymphocytes of healthy individuals, exerting protective or sensitizing action depending on concentration, cell radiosensitivity, dose of irradiation, and relative biological effectiveness. PMID 28230819 Domina, Experimental Oncology, 2016
- Diabetes mellitus in children (adjunct therapy) Human observational
- Clinico-metabolic investigations showed efficacy of thymalin as an immunomodulator in multimodality therapy of diabetes mellitus in children. PMID 2695919 Kurbanov et al., Problemy endokrinologii, 1989
- Trauma — prevention and treatment of infectious complications Human observational
- In 23 patients with critical trauma, complex treatment including thymalin improved clinical course of trauma disease and normalized immune indices. PMID 6547012 Gurevich et al., Vestnik khirurgii, 1984
- Ophthalmic herpes (adjunct immunotherapy) Human observational
- Therapeutic efficacy of thymalin assessed in 80 patients with ophthalmic herpes; thymic hormone preparations recommended for protracted conditions, with neutrophil injury index and secretory IgA in lacrimal fluid used to monitor immunomodulating therapy. PMID 1763455 Mal'khanov et al., Vestnik oftalmologii, 1991
- AIDS / HIV (T-lymphocyte restoration) Human observational
- Thymalin normalized LDH isoenzyme spectrum and cyclase system in lymphocytes of AIDS patients, promoted expression of differentiation antigens on T-lymphocyte surfaces, restored T-lymphocyte functional activity, and correlated with clinical improvement. PMID 2382426 Khavinson et al., Voprosy meditsinskoi khimii, 1990
- Infant/early childhood diseases (bacterial infections, pneumonia, bronchitis) Human observational
- Thymalin evaluated in diseases of early infancy including bacterial infections, bronchitis, laryngitis, tracheitis, and pneumonia in neonates, premature infants, and young children. PMID 3840883 Trofimenko et al., Pediatriia, 1985
- Cerebral palsy (rehabilitative adjunct) Human observational
- In 22 children with cerebral palsy (spastic diplegia) and frequent intercurrent infections, thymalin in complex rehabilitative therapy was associated with improvement in neurological defect in 54.55% of children with impaired immunocompetent system function one month after treatment. PMID 3878053 Mamonova, Zhurnal nevropatologii, 1985
Safety signals
- Thymalin therapy was 'not conducive to a rapid abatement of acute symptoms' in herpetic stomatitis, suggesting limited acute efficacy in some conditions and a need to weigh expected benefits against timing of response PMID 8191521
- In dysentery patients, thymalin (unlike indomethacin) inhibited antigen-specific T-lymphocyte adhesiveness while normalizing nonspecific adhesiveness — differential immunomodulatory effects may not be uniformly beneficial across all immune parameters PMID 2441548
- Thymalin exerted 'no substantial effect' on chemotaxis and phagocytosis of leukocytes, content of immunoglobulins, or circulating immune complexes in non-specific pulmonary disease patients — efficacy appears selective and not universal across all immune functions PMID 2741122
- In COVID-19 severe patients, hospital mortality in the Thymalin group was 20.6%, indicating that a substantial proportion of treated patients still died despite Thymalin use — it is not curative in severe disease PMID 36169363
Protocol
10 mg subcutaneous injection, once daily. Cycle: 10 days.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Not specified (described as 'relatively small doses') | 5 ml, 4–6 injections per treatment course | One course (number of days not specified) | human | Research PMID 2741122 |
| subcutaneous injection | 10 mg | once daily · 10 days | biohackers and longevity-focused adults, often 40+ | [Community] |
| subcutaneous injection | 10 mg | once daily · 10 days, repeated twice per year (e.g. spring and fall) | longevity-focused biohackers and older adults seeking immune rejuvenation | [Community] |
| subcutaneous injection | 5 mg | once daily · 10 days | biohackers newer to Thymalin or those preferring a conservative starting dose | [Community] |
| subcutaneous injection | 10 mg | once daily · 10 days, repeated once per year | adults 50+ pursuing longevity and immune system support | [Community] |
| subcutaneous injection | 10 mg | once daily · 10 days | biohackers stacking Thymalin with Epithalon for a combined longevity protocol | [Community] |
| subcutaneous injection | 1 mg | once daily · 20 days | cost-conscious biohackers or those experimenting with micro-dosing approaches | [Community] |
Blends containing this peptide
All studies (33)
- PMID 1481512 Human observational
Ischemic heart disease / angina pectoris - PMID 1763455 Human observational
Ophthalmic herpes (adjunct immunotherapy) - PMID 2014686 Human observational
Cervical carcinoma and uterine cancer (adjunct to radiotherapy/hormonotherapy) - PMID 2080155 Human observational
Pulmonary tuberculosis (adjunct to chemotherapy) - PMID 2160161 Human observational
Multiple sclerosis (homeostatic correction) - PMID 2163147 Human observational
Therapy-resistant schizophrenia (adjunct therapy) - PMID 2245808 Human observational
Cervical carcinoma and uterine cancer (adjunct to radiotherapy/hormonotherapy) - PMID 2382426 Human observational
AIDS / HIV (T-lymphocyte restoration) - PMID 2609748 Human observational
Psoriasis (immunomodulation) - PMID 2617987 Human observational
Pulmonary tuberculosis (adjunct to chemotherapy) - PMID 2695919 Human observational
Diabetes mellitus in children (adjunct therapy) - PMID 2741122 Human observational
Non-specific lung diseases (immunocorrection) - PMID 2750120 Human observational
Chronic lymphoid leukemia (adjunct therapy) - PMID 3488603 Human observational
Ischemic heart disease / angina pectoris - PMID 3754668 Human observational
Acute peritonitis (adjunct therapy) - PMID 3840883 Human observational
Infant/early childhood diseases (bacterial infections, pneumonia, bronchitis) - PMID 3878053 Human observational
Cerebral palsy (rehabilitative adjunct) - PMID 6547012 Human observational
Trauma — prevention and treatment of infectious complications - PMID 8191521 Human observational
Herpetic stomatitis in children - PMID 9670669 Human observational
Chronic lymphoid leukemia (adjunct therapy) - PMID 10424021 Human observational
Parkinsonism (adjunct therapy) - PMID 12577695 Human observational
Geroprotection / longevity and age-related disease prevention - PMID 14523363 Human observational
Geroprotection / longevity and age-related disease prevention - PMID 28230819 Human observational
Radiation-induced cytogenetic effects (modification) - PMID 33237528 Mixed
COVID-19 (severe) — immunomodulation and reduction of cytokine storm - PMID 36169363 Mixed
COVID-19 (severe) — immunomodulation and reduction of cytokine storm - PMID 37686182 Mixed
COVID-19 (severe) — immunomodulation and reduction of cytokine storm - PMID 2326818
- PMID 2441548
In dysentery patients, thymalin (unlike indomethacin) inhibited antigen-specific T-lymphocyte adhesiveness while normalizing nonspecific adhesiveness — differen - PMID 3754913
- PMID 6546722
- PMID 35408963 In vitro only
Inflammatory and proliferative modulation in monocyte/macrophage cells (in vitro) - PMID 38431810 Animal studies only
Reparative osteogenesis / bone defect healing